New drug combo shows promise for Tough-to-Treat melanoma
NCT ID NCT03501368
First seen Nov 01, 2025 · Last updated Apr 28, 2026 · Updated 21 times
Summary
This early-phase study tested a combination of two targeted drugs, trametinib and ceritinib, in 27 adults with advanced melanoma that could not be removed by surgery and had stopped responding to standard treatments. The main goals were to find the safest dose and see if the combination could shrink tumors. The study is complete, and results help guide future research on this drug pair.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for UNRESECTABLE MELANOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
H. Lee Moffitt Cancer Center and Research Institute
Tampa, Florida, 33612, United States
Conditions
Explore the condition pages connected to this study.